Acelrx Pharmaceuticals Inc., of Redwood City, Calif., said partner Grunenthal Group, of Aachen, Germany, submitted a marketing authorization application (MAA) to the EMA for Acelrx's Zalviso, a drug-device combination for the management of moderate to severe acute pain in adult patients in a medically supervised environment.